Maximizing ADC effectiveness against reduced expression of the target antigen
18 Jun 2025
Target Selection
- Are ADCs based on bispecific or biparatopic antibodies more effective in enhancing target cell binding compared to monospecific antibody-based ADCs?
- Does a high-potency payload improve efficacy against targets with low or heterogeneous expression, despite the downside of increased systemic toxicity, which may limit the allowable dose?
- Does bystander activity provide clinical benefits?
Industry Expert
